VENUS CONCEPT INC (VERO)

US92332W2044 - Common Stock

0.3205  0 (-0.68%)

After market: 0.3205 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to VERO. VERO was compared to 187 industry peers in the Health Care Equipment & Supplies industry. VERO may be in some trouble as it scores bad on both profitability and health. VERO is valued expensive and it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

VERO had negative earnings in the past year.
VERO had a negative operating cash flow in the past year.
VERO had negative earnings in each of the past 5 years.
In the past 5 years VERO always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of VERO (-69.38%) is worse than 74.87% of its industry peers.
With a Return On Equity value of -496.11%, VERO is not doing good in the industry: 87.70% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -69.38%
ROE -496.11%
ROIC N/A
ROA(3y)-29.74%
ROA(5y)-32.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

VERO's Gross Margin of 67.68% is fine compared to the rest of the industry. VERO outperforms 73.80% of its industry peers.
In the last couple of years the Gross Margin of VERO has grown nicely.
The Profit Margin and Operating Margin are not available for VERO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y9.61%

More info and screens

1

2. Health

2.1 Basic Checks

VERO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VERO has more shares outstanding
VERO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VERO has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -5.77, we must say that VERO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.77, VERO is not doing good in the industry: 72.19% of the companies in the same industry are doing better.
VERO has a Debt/Equity ratio of 3.40. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 3.40, VERO is doing worse than 87.17% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.4
Debt/FCF N/A
Altman-Z -5.77
ROIC/WACCN/A
WACC4.93%

2.3 Liquidity

VERO has a Current Ratio of 1.86. This is a normal value and indicates that VERO is financially healthy and should not expect problems in meeting its short term obligations.
VERO has a Current ratio of 1.86. This is in the lower half of the industry: VERO underperforms 70.05% of its industry peers.
VERO has a Quick Ratio of 1.18. This is a normal value and indicates that VERO is financially healthy and should not expect problems in meeting its short term obligations.
VERO's Quick ratio of 1.18 is on the low side compared to the rest of the industry. VERO is outperformed by 68.98% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.18

More info and screens

3

3. Growth

3.1 Past

The earnings per share for VERO have decreased strongly by -15.56% in the last year.
Looking at the last year, VERO shows a very negative growth in Revenue. The Revenue has decreased by -18.57% in the last year.
Measured over the past years, VERO shows a very strong growth in Revenue. The Revenue has been growing by 28.26% on average per year.
EPS 1Y (TTM)-15.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-0.71%
Revenue growth 5Y28.26%
Sales Q2Q%-14.81%

3.2 Future

The Earnings Per Share is expected to grow by 21.42% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -2.59% on average over the next years.
EPS Next Y-1.6%
EPS Next 2Y28.8%
EPS Next 3Y21.42%
EPS Next 5YN/A
Revenue Next Year-17.86%
Revenue Next 2Y-7.4%
Revenue Next 3Y-2.59%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VERO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as VERO's earnings are expected to grow with 21.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.8%
EPS Next 3Y21.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VERO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VENUS CONCEPT INC

NASDAQ:VERO (12/23/2024, 5:49:05 PM)

After market: 0.3205 0 (0%)

0.3205

0 (-0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners25.41%
Inst Owner Change-9.81%
Ins Owners2.55%
Ins Owner Change0%
Market Cap2.33M
Analysts47.5
Price Target10.81 (3272.85%)
Short Float %1.53%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-56.48%
Min EPS beat(2)-108.38%
Max EPS beat(2)-4.58%
EPS beat(4)0
Avg EPS beat(4)-46.69%
Min EPS beat(4)-108.38%
Max EPS beat(4)-4.58%
EPS beat(8)2
Avg EPS beat(8)-20.68%
EPS beat(12)3
Avg EPS beat(12)-30.31%
EPS beat(16)4
Avg EPS beat(16)-25.37%
Revenue beat(2)0
Avg Revenue beat(2)-9.54%
Min Revenue beat(2)-14.85%
Max Revenue beat(2)-4.24%
Revenue beat(4)1
Avg Revenue beat(4)-9.35%
Min Revenue beat(4)-20.82%
Max Revenue beat(4)2.5%
Revenue beat(8)3
Avg Revenue beat(8)-4.34%
Revenue beat(12)4
Avg Revenue beat(12)-4.56%
Revenue beat(16)6
Avg Revenue beat(16)-3.48%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.73%
EPS NQ rev (3m)1.33%
EPS NY rev (1m)1.18%
EPS NY rev (3m)1.18%
Revenue NQ rev (1m)-0.61%
Revenue NQ rev (3m)-11.8%
Revenue NY rev (1m)-5.03%
Revenue NY rev (3m)-5.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-8.02
EYN/A
EPS(NY)-2.34
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS9.26
BVpS1.39
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.38%
ROE -496.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.68%
FCFM N/A
ROA(3y)-29.74%
ROA(5y)-32.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y9.61%
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 3.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.73%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.18
Altman-Z -5.77
F-Score3
WACC4.93%
ROIC/WACCN/A
Cap/Depr(3y)6.99%
Cap/Depr(5y)16.38%
Cap/Sales(3y)0.33%
Cap/Sales(5y)0.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
EPS Next Y-1.6%
EPS Next 2Y28.8%
EPS Next 3Y21.42%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-0.71%
Revenue growth 5Y28.26%
Sales Q2Q%-14.81%
Revenue Next Year-17.86%
Revenue Next 2Y-7.4%
Revenue Next 3Y-2.59%
Revenue Next 5YN/A
EBIT growth 1Y4.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.88%
EBIT Next 3Y24.68%
EBIT Next 5YN/A
FCF growth 1Y67.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.51%
OCF growth 3YN/A
OCF growth 5YN/A